Kaouk Jihad, Aminsharifi Alireza, Sawczyn Guilherme, Kim Soodong, Wilson Clark A, Garisto Juan, Fareed Khaled
Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH; Department of Urology, Shiraz University of Medical Sciences, Shiraz, Iran.
Urology. 2020 Jun;140:77-84. doi: 10.1016/j.urology.2019.11.086. Epub 2020 Mar 3.
To present a comprehensive report regarding our experience with single-port robotic surgery in our first 100 consecutive patients. We describe the diversity of procedures that can be performed with this platform as well as the challenges and complications we had with the application of this novel technology.
Between September 2018 and August 2019, data on 100 patients who underwent single-port robotic surgery were consecutively collected. Preoperative, intraoperative and early postoperative outcomes after various urologic procedures were recorded and analyzed.
During the study period, 100 patients (age [range] 35-84 years; 88 [88%] Male) underwent various single-port robotic surgeries for different indications (Retroperitoneal [n = 14], Pelvic surgeries [n = 86]). Transperitoneal (n = 37), extraperitoneal (n = 53) and transvesical (n = 10) approaches have been used to access the target organs. Of these procedures, 73 (73%) were for different oncological indications: Radical prostatectomy (n = 60), Partial nephrectomy (n = 6), Retroperitoneal lymph node dissection (n = 1) and Radical cystectomy with intracorporeal diversion (n = 6). Surgery was successfully completed in all but 1 patient, in whom the surgery was converted to open surgery due to dense adhesions and failure to progress. Grades II-III postoperative complications were detected in (n = 9) patients.
The purpose-built single-port robotic platform can be safely incorporated into the minimally invasive armamentarium. A wide range of pelvic and retroperitoneal urological procedures can be done with different approaches using this platform. Randomized trials with adequate sample size and postoperative follow up period is advisable for further evaluation of the outcomes and to determine the added value of this emerging technology.
就我们连续100例患者的单孔机器人手术经验提供一份全面报告。我们描述了使用该平台可进行的手术的多样性,以及我们在应用这项新技术时遇到的挑战和并发症。
在2018年9月至2019年8月期间,连续收集了100例行单孔机器人手术患者的数据。记录并分析了各种泌尿外科手术后的术前、术中和术后早期结果。
在研究期间,100例患者(年龄[范围]35 - 84岁;88例[88%]为男性)因不同适应证接受了各种单孔机器人手术(腹膜后[n = 14],盆腔手术[n = 86])。采用经腹(n = 37)、腹膜外(n = 53)和经膀胱(n = 10)入路来接近目标器官。在这些手术中,73例(73%)是针对不同的肿瘤适应证:根治性前列腺切除术(n = 60)、部分肾切除术(n = 6)、腹膜后淋巴结清扫术(n = 1)和根治性膀胱切除术加体内改道术(n = 6)。除1例患者外,所有手术均成功完成,该例患者因粘连严重且手术无法进展而转为开放手术。(n = 9)例患者检测到Ⅱ - Ⅲ级术后并发症。
专门设计的单孔机器人平台可安全地纳入微创器械库。使用该平台可通过不同入路完成广泛的盆腔和腹膜后泌尿外科手术。建议进行具有足够样本量和术后随访期的随机试验,以进一步评估结果并确定这项新兴技术的附加价值。